Document is current
Any future updates will be listed below
-
Authors
Brentnall, Adam R. http://orcid.org/0000-0001-6327-4357
Warren, Ruth
Harkness, Elaine F.
Astley, Susan M.
Wiseman, Julia
Fox, Jill
Fox, Lynne
Eriksson, Mikael
Hall, Per
Cuzick, Jack
Evans, D. Gareth
Howell, Anthony
-
Funding
Funding for this research was provided by:
National Institute for Health Research (PB-PG-0110-21342)
Genesis Breast Cancer Prevention (GA09-001/GA10-002)
Cancer Research UK (C569/A16891)
- License Information
-
More Information
Article History
Received: 17 February 2020
Accepted: 10 September 2020
First Online: 29 September 2020
Ethics approval and consent to participate
: Women in both FH-Risk (no tamoxifen) and TAM-PREV (tamoxifen) cohorts provided informed written consent for use of their data and mammograms for this research. FH-Risk was approved by Greater Manchester Central Research Ethics committee, Ref: 10/H1008/24; TAM-PREV approved by Greater Manchester West Research Ethics Committee, Ref: 11/H1014/4.
: Not applicable.
: Prof Evans and Howell report receiving consultancy fees from AstraZeneca. Prof Cuzick has received funding from Sanofi-Aventis and AstraZeneca, and is a paid member of a speaker’s bureau for AstraZeneca. Prof Cuzick and Dr Brentnall report receiving royalty payments through Cancer Research UK for commercial use of the Tyrer–Cuzick algorithm to assess breast cancer risk. None of the other authors report any conflict of interest.
